Trending menu:
Oncology
-
5 June 2019 News
Massive Bio teams up with Biden Cancer Initiative to boost oncology clinical trials access
Massive Bio, a US-based provider of precision medicine and patient centric clinical trial matching services, has partnered in the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC).
-
5 June 2019 News
Tempus introduces TIME trial service to match cancer patients to clinical trials
Medical technology company Tempus has launched a new service that uses artificial intelligence to quickly match cancer patients to clinical trials.
-
26 April 2019 News
UK researchers call for better access to cancer drug trials
Researchers at Institute of Cancer Research, London (ICR) have published a manifesto to drive access to cancer drugs after a survey found patient delays for new therapies. The survey of...
-
3 April 2019 Comment
What are the top biomarkers in oncology clinical trials?
Biomarkers used in clinical studies may verify the mechanism of action of a drug, guide subject and dose selection and minimise patient safety risks.
-
22 March 2019 News
Health Quest to deploy IBM Watson for Clinical Trial Matching
Health Quest Systems has signed an agreement to deploy IBM Watson for Clinical Trial Matching, a cognitive computing system, to increase participation in clinical trials.
-
6 March 2019 News
ORNL researchers develop AI based tool to match cancer patients with clinical trials
A team of researchers from the Department of Energy’s (DOE) Oak Ridge National Laboratory (ORNL) Health Data Sciences Institute in the US has developed an artificial intelligence (AI) based digital...
-
5 March 2019 Digital Disruption
Embleema, Gustave Roussy to develop blockchain-based applications for cancer research
Embleema has partnered with Gustave Roussy Institut to develop blockchain-based health data sharing applications to accelerate cancer research.
-
26 February 2019 News
Analysis finds increasing early-stage trials for rare cancers
A new analysis by the National Cancer Center Hospital in Japan has found that the focus of early-stage clinical trials is shifting from major cancer killers to rare types of...
-
19 February 2019 News
Leukemia & Lymphoma Society to adopt Saama LSAC in Beat AML trial
US-based non-profit Leukemia & Lymphoma Society (LLS) has partnered with data analytics company Saama Technologies to implement Life Science Analytics Cloud (LSAC) in its Beat AML Master Clinical Trial. Saama’s...
-
6 February 2019 Analysis
Sandoz Abandons US Development of Rixathon
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to have Rixathon approved in the US